Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical PHMB for cutaneous leishmaniasis
PACTR202610684727895Phase 2Not yet recruiting
- Sponsor
- Vaccine Research Centre, University of Nigeria
- Start
- Oct 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of polihexanide in cutaneous leishmaniasis (CL) (2 arms), sponsored by Vaccine Research Centre, University of Nigeria. Primary endpoint: Final clinical cure rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
polihexanide
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on PACTR202610684727895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610684727895.